- Home
- TBPH vs CCXI Comparison
TBPH vs CCXI Comparison
Compare TBPH & CCXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TBPH | CCXI |
|---|---|---|
| Founded | 2013 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 908.9M | 883.4M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | TBPH | CCXI |
|---|---|---|
| Price | $16.87 | $15.15 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $18.40 | N/A |
| AVG Volume (30 Days) | 576.4K | ★ 3.0M |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 279.13 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,386,000.00 | N/A |
| Revenue This Year | $8.46 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.99 | $10.09 |
| 52 Week High | $21.03 | $19.69 |
Technical Indicators
Market Signals| Indicator | TBPH | CCXI |
|---|---|---|
| Relative Strength Index (RSI) | 50.80 | 57.23 |
| Support Level | $16.80 | $10.13 |
| Resistance Level | $17.17 | $19.69 |
| Average True Range (ATR) | 0.06 | 1.15 |
| MACD | -0.02 | -0.17 |
| Stochastic Oscillator | 33.33 | 75.20 |
Price Performance
Historical ComparisonAbout TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
About CCXI Churchill Capital Corp XI Class A Ordinary Shares
Churchill Capital Corp XI is a blank check company.